The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cancer service line multidisciplinary cancer care assessment: Current state analysis and implications for tumor board redesign.
 
Jim Doolin
Other Relationship - CRICO
 
Peter Whooley
No Relationships to Disclose
 
Lauren Curtis
No Relationships to Disclose
 
Rolf Freter
No Relationships to Disclose
 
Jason Freed
No Relationships to Disclose
 
Matthew Koomey
No Relationships to Disclose
 
Shakeeb Yunus
No Relationships to Disclose
 
Mose Hayes
No Relationships to Disclose
 
Stefan Balan
No Relationships to Disclose
 
Kelly Downey
No Relationships to Disclose
 
Panos Fidias
No Relationships to Disclose
 
Meghan Shea
Consulting or Advisory Role - AstraZeneca; Eisai; Genmab; GlaxoSmithKline; Nile Medical
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); GlaxoSmithKline; Lilly (Inst); Pfizer (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - Genmab
 
Corrine Zarwan
Research Funding - EMD Serono; Novartis; Tesaro
 
Paul Hesketh
Consulting or Advisory Role - UpToDate
 
William Decaneas
Employment - Beth Israel Deaconess Medical Center; Tufts Medical Center
 
David Avigan
Honoraria - Chugai Pharma; Engage Health Media; MD Education USA LLC Arcelix/Kite SAB)
Consulting or Advisory Role - Arcelix; Caribou Biosciences; Celgene; Chugai Pharma; Karyopharm Therapeutics; Kite, a Gilead Company; Legend Biotech; Merck; Parexel; Partner Therapeutics; Regeneron; Takeda
Research Funding - Abbvie; Celgene; CTN NIHLBI; Kite, a Gilead Company; MMRF Networks of Excellence Grant
Patents, Royalties, Other Intellectual Property - 1889 “Lenalidomide Enhances Immune Response to DC/MM Fusion Vaccine”. It issued in Australia as patent no. 2016243629 on 8.30.2017, and in the US as patent no. 11, 026,921 on 9/29/2017, entitled “Compositions and Methods of Treating Cancer",2018-087 “Use
Expert Testimony - Beland v. McNulty
Travel, Accommodations, Expenses - Arcelix; Bristol-Myers Squibb; Caribou Biosciences; Celgene; Chugai Pharma; Karyopharm Therapeutics; Kite, a Gilead Company; Legend Biotech; Merck; Parexel; Partner Therapeutics; Regeneron; Takeda
 
Jessica Zerillo
Employment - Harvard Medical Faculty Physicians/ BIDMC
Expert Testimony - CRICO